Downregulation or loss of chemerin/RARRES2 in malignancies can modulate the tumor microenvironment and tumor immune responses and act as both a pro- and anti-inflammatory mediator compared to the normal tissue counterparts (Shin et al., 2018). Here, RARRES2 is linked to neoplasm.